Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
Identifieur interne : 007F87 ( Main/Exploration ); précédent : 007F86; suivant : 007F88Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
Auteurs : Alexandra F. Leary [Royaume-Uni, Canada, Pays-Bas, France, Allemagne, Japon, Australie] ; Wedad M. Hanna ; Marc J. Van De Vijver ; Frederique Penault-Llorca ; Josef Rüschoff ; Robert Y. Osamura ; Michael Bilous ; Mitch DowsettSource :
- Journal of clinical oncology [ 0732-183X ] ; 2009.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
The human epidermal receptor-2 (HER-2) is overexpressed or amplified in 15% to 25% of breast cancers. Determination of HER-2 tumor status offers clinically useful information, as it selects patients who may benefit from treatment with trastuzumab, the monoclonal antibody against HER-2. Currently approved methods for HER-2 testing include immunohistochemistry or fluorescent in situ hybridization using tumor tissue. A fragment of HER-2 composed of its extracellular domain (ECD) can also be detected in the serum of some patients with breast cancer. As an easily accessible tumor marker, it could offer additional useful prognostic or predictive information. This review will briefly address the biology of the circulating HER-2 ECD and discuss the evidence to support the role, if any, for measuring HER-2 ECD levels in women with breast cancer. In particular, we focus on the value and limitations of serum ECD in both early and advanced breast cancer in the following clinical contexts: as a marker of HER-2 tumor tissue status; clinical implications of raised levels in women who have a tumor not overexpressing HER-2; as a prognostic indicator and as a predictor of response to treatment; and as a monitoring tool for early recurrence. On the basis of our review of the literature, we conclude that there is currently insufficient evidence to support the use of serum HER-2 ECD in the routine management of individual patients with breast cancer. This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer.
Affiliations:
- Allemagne, Australie, Canada, France, Japon, Pays-Bas, Royaume-Uni
- Angleterre, Auvergne (région administrative), Auvergne-Rhône-Alpes, District de Kassel, Grand Londres, Hesse (Land), Hollande-Septentrionale
- Amsterdam, Cassel (Hesse), Clermont-Ferrand, Londres
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 002E73
- to stream PascalFrancis, to step Curation: 003147
- to stream PascalFrancis, to step Checkpoint: 002717
- to stream Main, to step Merge: 008686
- to stream Main, to step Curation: 007F87
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients</title><author><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sunnybrook and Women's College, Health Science Center</s1><s2>Toronto</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Toronto</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Netherlands Cancer Institute</s1><s2>Amsterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Jean Perrin</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Klinikum Kassel</s1><s2>Kassel</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Tokai University School of Medicine</s1><s2>Kanagawa</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Tokai University School of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Westmead Hospital</s1><s2>Westmead, New South Wales</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Westmead Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hanna, Wedad M" sort="Hanna, Wedad M" uniqKey="Hanna W" first="Wedad M." last="Hanna">Wedad M. Hanna</name></author><author><name sortKey="Van De Vijver, Marc J" sort="Van De Vijver, Marc J" uniqKey="Van De Vijver M" first="Marc J." last="Van De Vijver">Marc J. Van De Vijver</name></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name></author><author><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name></author><author><name sortKey="Osamura, Robert Y" sort="Osamura, Robert Y" uniqKey="Osamura R" first="Robert Y." last="Osamura">Robert Y. Osamura</name></author><author><name sortKey="Bilous, Michael" sort="Bilous, Michael" uniqKey="Bilous M" first="Michael" last="Bilous">Michael Bilous</name></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">09-0179842</idno><date when="2009">2009</date><idno type="stanalyst">PASCAL 09-0179842 INIST</idno><idno type="RBID">Pascal:09-0179842</idno><idno type="wicri:Area/PascalFrancis/Corpus">002E73</idno><idno type="wicri:Area/PascalFrancis/Curation">003147</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002717</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002717</idno><idno type="wicri:doubleKey">0732-183X:2009:Leary A:value:and:limitations</idno><idno type="wicri:Area/Main/Merge">008686</idno><idno type="wicri:Area/Main/Curation">007F87</idno><idno type="wicri:Area/Main/Exploration">007F87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients</title><author><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Royal Marsden Hospital</s1><s2>London</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Sunnybrook and Women's College, Health Science Center</s1><s2>Toronto</s2><s3>CAN</s3></inist:fA14><country>Canada</country><wicri:noRegion>Toronto</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Netherlands Cancer Institute</s1><s2>Amsterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Jean Perrin</s1><s2>Clermont-Ferrand</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Klinikum Kassel</s1><s2>Kassel</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Kassel</region><settlement type="city">Cassel (Hesse)</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Tokai University School of Medicine</s1><s2>Kanagawa</s2><s3>JPN</s3></inist:fA14><country>Japon</country><wicri:noRegion>Tokai University School of Medicine</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Westmead Hospital</s1><s2>Westmead, New South Wales</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Westmead Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hanna, Wedad M" sort="Hanna, Wedad M" uniqKey="Hanna W" first="Wedad M." last="Hanna">Wedad M. Hanna</name></author><author><name sortKey="Van De Vijver, Marc J" sort="Van De Vijver, Marc J" uniqKey="Van De Vijver M" first="Marc J." last="Van De Vijver">Marc J. Van De Vijver</name></author><author><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name></author><author><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name></author><author><name sortKey="Osamura, Robert Y" sort="Osamura, Robert Y" uniqKey="Osamura R" first="Robert Y." last="Osamura">Robert Y. Osamura</name></author><author><name sortKey="Bilous, Michael" sort="Bilous, Michael" uniqKey="Bilous M" first="Michael" last="Bilous">Michael Bilous</name></author><author><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name></author></analytic><series><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of clinical oncology</title><title level="j" type="abbreviated">J. clin. oncol.</title><idno type="ISSN">0732-183X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast cancer</term><term>C-Onc gene</term><term>Cancerology</term><term>Extracellular</term><term>Human</term><term>Human Epidermal growth factor Receptor 2</term><term>Protooncogene</term><term>Serum</term><term>erbB2 Gene</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer du sein</term><term>Gène onc cellulaire</term><term>Gène erbB2</term><term>Protooncogène</term><term>Extracellulaire</term><term>Sérum</term><term>Homme</term><term>Cancérologie</term><term>Récepteur HER2</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The human epidermal receptor-2 (HER-2) is overexpressed or amplified in 15% to 25% of breast cancers. Determination of HER-2 tumor status offers clinically useful information, as it selects patients who may benefit from treatment with trastuzumab, the monoclonal antibody against HER-2. Currently approved methods for HER-2 testing include immunohistochemistry or fluorescent in situ hybridization using tumor tissue. A fragment of HER-2 composed of its extracellular domain (ECD) can also be detected in the serum of some patients with breast cancer. As an easily accessible tumor marker, it could offer additional useful prognostic or predictive information. This review will briefly address the biology of the circulating HER-2 ECD and discuss the evidence to support the role, if any, for measuring HER-2 ECD levels in women with breast cancer. In particular, we focus on the value and limitations of serum ECD in both early and advanced breast cancer in the following clinical contexts: as a marker of HER-2 tumor tissue status; clinical implications of raised levels in women who have a tumor not overexpressing HER-2; as a prognostic indicator and as a predictor of response to treatment; and as a monitoring tool for early recurrence. On the basis of our review of the literature, we conclude that there is currently insufficient evidence to support the use of serum HER-2 ECD in the routine management of individual patients with breast cancer. This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>France</li><li>Japon</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Auvergne (région administrative)</li><li>Auvergne-Rhône-Alpes</li><li>District de Kassel</li><li>Grand Londres</li><li>Hesse (Land)</li><li>Hollande-Septentrionale</li></region><settlement><li>Amsterdam</li><li>Cassel (Hesse)</li><li>Clermont-Ferrand</li><li>Londres</li></settlement></list><tree><noCountry><name sortKey="Bilous, Michael" sort="Bilous, Michael" uniqKey="Bilous M" first="Michael" last="Bilous">Michael Bilous</name><name sortKey="Dowsett, Mitch" sort="Dowsett, Mitch" uniqKey="Dowsett M" first="Mitch" last="Dowsett">Mitch Dowsett</name><name sortKey="Hanna, Wedad M" sort="Hanna, Wedad M" uniqKey="Hanna W" first="Wedad M." last="Hanna">Wedad M. Hanna</name><name sortKey="Osamura, Robert Y" sort="Osamura, Robert Y" uniqKey="Osamura R" first="Robert Y." last="Osamura">Robert Y. Osamura</name><name sortKey="Penault Llorca, Frederique" sort="Penault Llorca, Frederique" uniqKey="Penault Llorca F" first="Frederique" last="Penault-Llorca">Frederique Penault-Llorca</name><name sortKey="Ruschoff, Josef" sort="Ruschoff, Josef" uniqKey="Ruschoff J" first="Josef" last="Rüschoff">Josef Rüschoff</name><name sortKey="Van De Vijver, Marc J" sort="Van De Vijver, Marc J" uniqKey="Van De Vijver M" first="Marc J." last="Van De Vijver">Marc J. Van De Vijver</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name></region></country><country name="Canada"><noRegion><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name></noRegion></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name></region></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name></region></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name></region></country><country name="Japon"><noRegion><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Leary, Alexandra F" sort="Leary, Alexandra F" uniqKey="Leary A" first="Alexandra F." last="Leary">Alexandra F. Leary</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007F87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007F87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:09-0179842
|texte= Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
}}
| This area was generated with Dilib version V0.6.33. |  |